IO Biotech将在2025年ESCO大会上展示IO 102-IO 103癌症疫苗加帕博利珠单抗的第三期和最终第二期试验结果

• Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma
• Poster presentation will share final data from Phase 2 basket trial (IOB-022/KN-D38) of IO102-IO103 cancer vaccine plus pembrolizumab for 1L treatment of solid tumors

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany from October 17-21, 2025.

The oral presentation will highlight the results from the randomized Phase 3 trial assessing the efficacy and safety of IO102-IO103 (IDO/PD-L1 vaccine) in combination with pembrolizumab vs pembrolizumab monotherapy in 1L advanced melanoma. In addition, final data from the Phase 2 basket trial with updated efficacy and safety data, median progression-free survival (PFS), landmark PFS and overall survival data, as well as biomarker and translational data for 1L treatment in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head and neck (SCCHN), will be presented in a poster session. Details of the presentations are as follows:

Late-breaking abstracts at ESMO are generally reserved for high-quality, new research findings from randomized Phase 2 or Phase 3 trials with implications for clinical practice or understanding of disease processes. Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.

The poster may be found on the "Posters & Publications" page of the IO Biotech website at the start of the meeting.